News
AWKNF
0.110
NaN%
--
Weekly Report: what happened at AWKNF last week (0422-0426)?
Weekly Report · 1d ago
Weekly Report: what happened at AWKNF last week (0415-0419)?
Weekly Report · 04/22 10:56
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Benzinga's psychedelic headlines roundup includes a look at the first two weeks of April 2024. Psilocybin could alter mechanisms associated with major depression and neurodegenerative diseases. Ancient Romans used to trip on hallucinogenic plants, archeologists say. Psycon's 2024 edition will take place in Colorado in May.
Benzinga · 04/17 13:13
Awakn Life Sciences Secures Funding Boost
TipRanks · 04/17 12:07
Weekly Report: what happened at AWKNF last week (0408-0412)?
Weekly Report · 04/15 10:49
Weekly Report: what happened at AWKNF last week (0401-0405)?
Weekly Report · 04/08 10:53
Awakn Life Sciences inks licensing partnership deal with Oklahoma-based clinic
Healthcare Awakn Life Sciences inks licensing partnership deal with Oklahoma-based clinic. The company also announced a new non-brokered financing on the CSE for gross proceeds of up to $1,000,000 to fund its working capital needs.Awakn inks additional licensing agreement with Oklahoma City-based Rivus Wellness and Research Institute.
Seeking Alpha · 04/03 12:41
Awakn Life Sciences Expands U.S. Presence, Secures Funding
TipRanks · 04/03 12:09
Weekly Report: what happened at AWKNF last week (0325-0329)?
Weekly Report · 04/01 10:51
Weekly Report: what happened at AWKNF last week (0318-0322)?
Weekly Report · 03/25 10:54
Weekly Report: what happened at AWKNF last week (0311-0315)?
Weekly Report · 03/18 10:52
Weekly Report: what happened at AWKNF last week (0304-0308)?
Weekly Report · 03/11 10:49
Weekly Report: what happened at AWKNF last week (0226-0301)?
Weekly Report · 03/04 10:52
Weekly Report: what happened at AWKNF last week (0219-0223)?
Weekly Report · 02/26 11:03
Weekly Report: what happened at AWKNF last week (0212-0216)?
Weekly Report · 02/19 11:05
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Benzinga's psychedelics headlines roundup includes a look at the last few days of January and the first two weeks of February 2024. A review of Indigenous psilocybin mushroom practices: An annotated bibliography. Psychedelics center developed a new rating scale for the effects of MDMA, ketamine and other drugs.
Benzinga · 02/15 15:55
Weekly Report: what happened at AWKNF last week (0205-0209)?
Weekly Report · 02/12 10:55
Weekly Report: what happened at AWKNF last week (0129-0202)?
Weekly Report · 02/05 11:02
Weekly Report: what happened at AWKNF last week (0122-0126)?
Weekly Report · 01/29 10:53
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
The Global Drug Survey has officially launched its 2024 edition. UK's first regular drug testing service to open in Bristol. The latest issue of the journal Psychedelic Medicine is out. University of Texas and Clusterbusters are conducting a survey on cluster headache medication and psychedelic use.
Benzinga · 01/26 17:33
More
Webull provides a variety of real-time AWKNF stock news. You can receive the latest news about Awakn Life Scien through multiple platforms. This information may help you make smarter investment decisions.
About AWKNF
Awakn Life Sciences Corp. is a Canada-based biotechnology company. The Company is engaged in the research, development, and delivery of psychedelic therapeutics (medicines and therapies) to treat addiction. The Company’s therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than traditional single drug receptor targets. It operates through three segments: the development segment, delivery segment, and corporate segment. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxymethamphetamine (MDMA)assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe. The corporate segment, which comprises corporate income and expense items. The Company operates in the United Kingdom (UK), Norway, Ireland, and Canada.